The efficacy and safety of epirubicin and cyclophosphamide followed by paclitaxel and trastuzumab in a neoadjuvant setting in patients with HER2-positive breast cancer were evaluated in the Taxol Epirubicin Cyclophosphamide Herceptin NeOadjuvant study (TECHNO) [36]. This evidence concerns the gene ERBB2 and breast cancer.